A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Gynecol Oncol
Asıl Yazarlar: Bender, David, Sill, Michael W., Lankes, Heather A., Reyes, Henry D., Darus, Christopher J., Delmore, James E., Rotmensch, Jacob, Gray, Heidi J., Mannel, Robert S., Schilder, Jeanne M., Hunter, Mark I., McCourt, Carolyn K., Samuelson, Megan I., Leslie, Kimberly K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4642817/
https://ncbi.nlm.nih.gov/pubmed/26186911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.07.018
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller